about
Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosisRefocusing of B-cell responses following a single amino acid substitution in an antigenDesign of immunogenic and effective multi-epitope DNA vaccines for melanoma.Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesEfficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequencesRelative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA allelesIntracellular bacteria as targets and carriers for vaccination.Two major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunizationIn silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responsesInduction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine.Immunogenicity of a multi-epitope DNA vaccine against hantavirus.Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice.Moving towards improved vaccines for Toxoplasma gondii.Synthetic p55 tandem DNA vaccine against Pneumocystis carinii in rats.
P2860
Q24657081-A11EC746-5CDA-4018-9AFD-66BAA2AE46A2Q28367028-A1C2DC7A-8FFF-438B-B1BD-CA37A2C48857Q33606546-5756C937-766E-4EC6-96D6-B72E1F6FE23EQ33814863-82AFD1BA-57E8-4F09-8F1C-CEE66CF5C720Q33825216-8C8372F2-DADC-437D-B234-C07C9A2E481FQ33842771-107F4147-839A-4FDB-8214-1475C2CFC5EAQ34280918-04956111-A6B6-4860-B1DD-54B907EEA361Q34976792-3D7B5613-E558-4432-8C0D-CC6EB80C3ADEQ35198753-8AE172ED-13D7-4358-82CA-8C5F5BADBC01Q36113141-97C9A6A4-7667-4B1F-8582-57FE76BE5883Q36954135-6741908F-5F2F-4315-A182-BE9443375829Q40238006-EC3FDC61-8926-4CE4-A818-21C006F2F3A0Q40293033-1A3C11C6-6794-42BB-AF3F-AC63EA5B2B20Q40299563-E1EE311B-3D4B-4E75-962F-F4FEAD97F806Q47318857-96EAB80C-D3A2-4300-9372-6A947B246EECQ53099790-3D281FA8-DDD2-451D-A070-7DF6B5AD69E2
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Multi-epitope DNA vaccines.
@en
type
label
Multi-epitope DNA vaccines.
@en
prefLabel
Multi-epitope DNA vaccines.
@en
P2860
P356
P1476
Multi-epitope DNA vaccines.
@en
P2093
Suhrbier A
P2860
P2888
P304
P356
10.1038/ICB.1997.63
P577
1997-08-01T00:00:00Z
P6179
1051333266